Literature DB >> 11380948

Evidence for a novel polymorphism affecting both N-linked glycosylation and ligand binding of the IgG receptor IIIB (CD16).

K Yamamoto1, N Sugita, T Kobayashi, K Okuda, J G Van De Winkel, H Yoshie.   

Abstract

Immunoglobulin G Fc receptor IIIb (FcgammaRIIIb) is constitutively expressed on neutrophils, and has three allelic forms: FcgammaRIIIb-NA1, FcgammaRIIIb-NA2, and FcgammaRIIIb-SH. We identified two Japanese subjects in whom an A to G substitution at nt 221 changes asparagine (N) to serine (S) at amino acid position 45 in the FcgammaRIIIb-NA2 gene. FcgammaRIIIb-NA2-specific monoclonal antibodies (GRM1 and PEN1) did not bind to mutant neutrophils, which lack an N-linked glycosylation site. Furthermore, IgG3-mediated neutrophil phagocytosis by mutant was slightly increased as compared to wild-type donors (Note).

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11380948     DOI: 10.1034/j.1399-0039.2001.057004363.x

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN: 0001-2815


  3 in total

1.  Fcγ receptor IIIa single-nucleotide polymorphisms and haplotypes affect human IgG binding and are associated with lupus nephritis in African Americans.

Authors:  Chaoling Dong; Travis S Ptacek; David T Redden; Kui Zhang; Elizabeth E Brown; Jeffrey C Edberg; Gerald McGwin; Graciela S Alarcón; Rosalind Ramsey-Goldman; John D Reveille; Luis M Vilá; Michelle Petri; Aijian Qin; Jianming Wu; Robert P Kimberly
Journal:  Arthritis Rheumatol       Date:  2014-05       Impact factor: 10.995

Review 2.  Immunomodulation by IVIg and the Role of Fc-Gamma Receptors: Classic Mechanisms of Action after all?

Authors:  Sietse Q Nagelkerke; Taco W Kuijpers
Journal:  Front Immunol       Date:  2015-01-21       Impact factor: 7.561

Review 3.  Genetic Variation in Low-To-Medium-Affinity Fcγ Receptors: Functional Consequences, Disease Associations, and Opportunities for Personalized Medicine.

Authors:  Sietse Q Nagelkerke; David E Schmidt; Masja de Haas; Taco W Kuijpers
Journal:  Front Immunol       Date:  2019-10-03       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.